ERBB2 and cancer: The irreversible ErbB family receptor blocker, afatinib (BIBW 2992), which inhibits EGFR, HER2 and HER4 tyrosine kinases, has been shown to be effective in the elimination of cancer cells with HER2 gene mutations in cell lines and animal models (15–19).